Zacks Research Increases Earnings Estimates for AstraZeneca

AstraZeneca PLC (NASDAQ:AZN - Free Report) - Stock analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for AstraZeneca in a research report issued on Monday, December 30th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.07 for the quarter, up from their previous estimate of $1.06. The consensus estimate for AstraZeneca's current full-year earnings is $4.11 per share.

A number of other research analysts have also recently commented on the stock. UBS Group upgraded shares of AstraZeneca from a "sell" rating to a "neutral" rating in a report on Wednesday, November 20th. Erste Group Bank upgraded shares of AstraZeneca from a "hold" rating to a "buy" rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a "sell" rating to a "hold" rating in a research note on Wednesday, November 6th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $89.75.

AstraZeneca Trading Down 0.1 %

AZN stock traded down $0.05 during midday trading on Wednesday, reaching $65.52. The company's stock had a trading volume of 2,018,679 shares, compared to its average volume of 5,310,276. AstraZeneca has a 1 year low of $60.47 and a 1 year high of $87.68. The firm has a market capitalization of $203.15 billion, a price-to-earnings ratio of 31.35, a PEG ratio of 1.19 and a beta of 0.45. The stock has a fifty day simple moving average of $67.38 and a two-hundred day simple moving average of $75.57. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter last year, the business earned $0.87 EPS. The business's revenue was up 18.0% on a year-over-year basis.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Stratos Wealth Advisors LLC raised its stake in shares of AstraZeneca by 2.0% during the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock worth $522,000 after acquiring an additional 133 shares in the last quarter. Crumly & Associates Inc. lifted its holdings in shares of AstraZeneca by 2.2% during the 3rd quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock valued at $518,000 after purchasing an additional 143 shares during the last quarter. Cobblestone Capital Advisors LLC NY boosted its position in shares of AstraZeneca by 4.6% in the 2nd quarter. Cobblestone Capital Advisors LLC NY now owns 3,529 shares of the company's stock worth $275,000 after purchasing an additional 154 shares in the last quarter. Harbour Investments Inc. boosted its position in shares of AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company's stock worth $686,000 after purchasing an additional 160 shares in the last quarter. Finally, Community Bank & Trust Waco Texas grew its stake in AstraZeneca by 2.8% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 5,890 shares of the company's stock worth $459,000 after buying an additional 162 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.